Calling for papers! Submit your research to our brand-new Network and Systems Medicine journal
About Network and Systems Medicine
Network and Systems Medicine is an open access, peer-reviewed journal focused on interdisciplinary approaches to exploiting the power of big data by applying network science and systems thinking to medicine. Network and Systems Medicine publishes high quality basic science, translational, and clinical research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technology reports, hypothesis articles, perspectives, and letters to the editor.
The journal coverage includes:
- Network science applied to medicine
- Mechanism-based disease definitions, diagnostics and therapies
- Network medicine and network pharmacology
- Multiscale modeling and medical simulation
- Multiscale medical data science and computing
- Virtual patient repositories and data analytics platforms
- Big data analytics in precision medicine
- Clinical validation of systems medicine approaches (including quali-quantitative methods)
- Multiscale approaches, e.g. translational and qualitative research and psycho-sociological variables
- Implementing systemic management in medicine in organizations and integrated healthcare networks
- Educational and training articles in systems medicine and network medicine methodologies for clinicians
Call for papers
Learn more about key topics covered and the editorial board behind the Network and Systems Medicine journal
Contribute to Network and Systems Medicine
Explore all the details at Drug Repurposing Central and submit your research today!
Looking for a Premier Publishing Portal for Drug Repurposing Research?
Created as a joint enterprise by REPO4EU and ScienceOpen, Drug Repurposing Central is the premier publishing portal for researchers specializing in drug repurposing, network medicine and precision healthcare. Our portal provides a comprehensive list of resources collating the latest research, and offers multiple publication channels, including preprints, journal articles, conference abstracts, reports, and books.
DrugRxiv, as a cornerstone within Drug Repurposing Central, enhances the portal by allowing researchers to share preliminary findings rapidly. This unique collection supports the drug repurposing community by providing a dedicated space for early results, fostering collaboration and innovation.
Researchers can actively participate in sharing and discussion within an open review environment, powered by ScienceOpen’s innovative discovery infrastructure. Developed under the Horizon Europe project, REPO4EU, which aspires to establish a European Platform for Drug Repurposing with global outreach, Drug Repurposing Central offers unparalleled access to publishing and reading resources at no cost. This portal is steadfast in its commitment to advancing Open Science, ensuring the utmost integrity of research outputs through consistent use of persistent identifiers and XML standards.
Our Drug Repurposing journal is back for its second issue
About Drug Repurposing
The Drug Repurposing journal aims to provide an interdisciplinary and cross-sectional overview of the various fields of research and applied sciences that work together to make successful drug repurposing projects a reality. High-throughput and high-content screening, in silico docking studies, pathway-based molecular pharmacology, bioinformatics, mining of peer-reviewed literature, patent documents, and side effect records, and design of drug repurposing trials are all part of this. We also welcome manuscripts that address strategic and ethical issues that are relevant in the broader context of drug repurposing, such as regulatory affairs, health technology assessment, and intellectual property. We especially welcome contributions that emphasize the specific integrative aspects of drug repurposing.
Drug Repurposing publishes high quality basic science, translational, and clinical research in the form of original research articles, comprehensive review articles, mini-reviews, rapid communications, brief reports, technology reports, hypothesis articles, perspectives, and letters to the editor. The Journal publishes under the Creative Commons Attribution 4.0 (CC BY) license to ensure broad dissemination and participation.
Official launch and editions
The official launch of the inaugural issue for the Drug Repurposing journal coincided with our latest RExPO24 conference in Munich back in July 2024. This first edition featured a robust collection of discussion articles, research papers and review articles, jointly portraying the breadth of the drug repurposing field. The goal is to catalyze progress, inspire collaboration and ultimately improve patient outcomes through the strategic repurposing of pharmaceuticals. Given the highly interdisciplinary nature of drug repurposing, multidisplinary is a cornerstone, and contributions from bioinformatics, cheminformatics, preclinical validation, clinical trials, ethics by design, freedom-to-operate, patenting strategies, business development, funding, regulatory, and reimbursement sectors are welcome.
Now, our Drug Repurposing journal is back with a second issue – read on for a sneak peek of everything that can be found inside and revisit past issues for key insights and collaborations.
Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)
Advancing Drug Discovery through Integrative Computational Models and AI Technologies
Looking for a Premier Publishing Portal for Drug Repurposing Research?
Created as a joint enterprise by REPO4EU and ScienceOpen, Drug Repurposing Central is the premier publishing portal for researchers specializing in drug repurposing, network medicine and precision healthcare. Our portal provides a comprehensive list of resources collating the latest research, and offers multiple publication channels, including preprints, journal articles, conference abstracts, reports, and books.
Researchers can actively participate in sharing and discussion within an open review environment, powered by ScienceOpen’s innovative discovery infrastructure. Developed under the Horizon Europe project, REPO4EU, which aspires to establish a European Platform for Drug Repurposing with global outreach, Drug Repurposing Central offers unparalleled access to publishing and reading resources at no cost. This portal is steadfast in its commitment to advancing Open Science, ensuring the utmost integrity of research outputs through consistent use of persistent identifiers and XML standards.
Introducing DrugRxiv: A Preprint Server Tailored for the Drug Repurposing Community
About DrugRxiv
DrugRxiv is a pioneering preprint server specifically designed for the drug Rrepurposing community, and one of the key collections under Drug Repurposing Central, our publishing portal. DrugRxiv serves as an open community resource, enabling researchers to share early-stage results in the field of drug repurposing easily and openly.
A preprint is an early version of a scientific manuscript and also a powerful tool that authors can now share publicly online before undergoing formal peer review. This practice, a cornerstone of Open Science, accelerates the spread of research findings, fostering open access and peer review. In general, preprints can be posted:
- before article submission to encourage open reviews and improve the paper’s quality before it is officially submitted,
- at the point of submission to a journal to make results available during the sometimes long peer review process, or
- at the time of publication as a postprint to make an open access version available.
The DrugRxiv submission system is uniquely equipped with automated checks to ensure scientific rigor and originality. SciScore evaluates the scientific quality, while Crossref performs similarity checks, aligning with the Open Science Strategy outlined for REPO4EU. Although currently funded and managed by REPO4EU, DrugRxiv is accessible to all researchers within the drug repurposing field.
Looking for a Premier Publishing Portal for Drug Repurposing Research?
Created as a joint enterprise by REPO4EU and ScienceOpen, Drug Repurposing Central is the premier publishing portal for researchers specializing in drug repurposing, network medicine and precision healthcare. Our portal provides a comprehensive list of resources collating the latest research, and offers multiple publication channels, including preprints, journal articles, conference abstracts, reports, and books.
DrugRxiv, as a cornerstone within Drug Repurposing Central, enhances the portal by allowing researchers to share preliminary findings rapidly. This unique collection supports the drug repurposing community by providing a dedicated space for early results, fostering collaboration and innovation.
Researchers can actively participate in sharing and discussion within an open review environment, powered by ScienceOpen’s innovative discovery infrastructure. Developed under the Horizon Europe project, REPO4EU, which aspires to establish a European Platform for Drug Repurposing with global outreach, Drug Repurposing Central offers unparalleled access to publishing and reading resources at no cost. This portal is steadfast in its commitment to advancing Open Science, ensuring the utmost integrity of research outputs through consistent use of persistent identifiers and XML standards.
Our newsletter is back for its second issue
REPO4EU has just reached its one-year milestone and what better way to celebrate than with a new installment of our official newsletter? Here’s a sneak peek of what you’ll find inside:
- The latest news on RExPO23 – the international conference on Systems Medicine, AI and Drug Repurposing coming to Stockholm this October 25-26.
- How to join our thriving drug repurposing community to get access to expert insights and matchmaking opportunities.
- An overview of our brand new one-stop publishing platform: Drug Repurposing Central
- Our collection of Knowledge Pills: a series of short explainer videos covering the core concepts behind REPO4EU
- Recap highlights from our recent meetings with the EMA Innovation Task Force and our Project Officer.
Click here to navigate to our second issue and don’t forget to subscribe!
Photo by Rinck Content Studio on Unsplash
Introducing our official newsletter
At REPO4EU we are starting the new year in style – and what better way to do that than with the launch of our official quarterly newsletter?
Ever since REPO4EU kicked-off, we have been setting the stage for what we believe will be the future – mechanism-based drug repurposing. Read on to discover the main highlights from our work these past 5 months as presented by our coordinator, Prof. Harald Schmidt. In this first issue you’ll find insights from our experts on ethics and AI, the project’s ongoing clinical trials and our contributions to the regulatory and legal landscape surrounding drug repurposing.
We’re also delighted to share a sneak peek on upcoming dissemination activities with the community – stay tuned for updates on REPO4EU’s open publishing portal and our national events to showcase the project in Spain, Germany, Austria and Sweden!
Sounds interesting? Click here to check out the full newsletter and make sure to subscribe!
Photo by Luca Onniboni on Unsplash
Our first press release is out!
Many exciting things are on the horizon for this September that we would like to share with everyone in the drug repurposing community!
REPO4EU - the Euro-Global platform for Mechanism-based Drug Repurposing is officially kicking off next month and with it also comes to life RExPO22 - the first international conference on drug repurposing.
You can read all about it in our first joint press release!
Photo by Utsav Srestha on Unsplash
A new piece on Alzheimer from our colleagues at STALICLA
Our colleague Emre Guney from STALICLA (a member of REPO4EU) is one of the co-authors of “A needle for Alzheimer’s in a haystack of claims data“.
In the era of big data, looking for insights in large datasets has become the norm — and health data are no exception. Combining systems-biology-driven, endophenotype-based analysis of drug targets with large-scale medical claims data points to sildenafil as a potential treatment opportunity for Alzheimer’s disease
Photo by David Matos on Unsplash
Sounds interesting?
Make sure to check out the full article in the link below
Network medicine for disease module identification and drug repurposing with the NeDRex platform
A new paper has been published recently under the title of Network medicine for disease module identification and drug repurposing with the NeDRex platform.
Sounds interesting?
You can navigate to the full text via the link below
Network pharmacology: curing causal mechanisms instead of treating symptoms
A new paper has been published recently under the title of Network pharmacology: curing causal mechanisms instead of treating symptoms.
Photo by Roberto Sorin on Unsplash
Sounds interesting?
Make sure to check out the full article in the link below